Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 759

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

Open access
Graus, Francesc, Vogrig, Alberto, Muñiz-Castrillo, Sergio, Antoine, Jean-Christophe G., Desestret, Virginie, Dubey, Divyanshu, Giometto, Bruno, Irani, Sarosh R., Joubert, Bastien, Leypoldt, Frank, McKeon, Andrew, Prüss, Harald, Psimaras, Dimitri, Thomas, Laure, Titulaer, Maarten J., Vedeler, Christian A., Verschuuren, Jan J., Dalmau, Josep, Honnorat, Jerome · 2021 · Neurology Neuroimmunology & Neuroinflammation

Abstract

OBJECTIVE: The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs) requires an increasing understanding of their clinical, immunologic, and oncologic heterogeneity. The 2004 PNS criteria are partially outdated due to advances in PNS research in the last 16 years leading to the identification of new phenotypes and antibodies that have transformed the diagnostic approach to PNS. Here, we propose updated diagnostic criteria for PNS. METHODS: A panel of experts developed by consensus a modified set of diagnostic PNS criteria for clinical decision making and research purposes. The panel reappraised the 2004 criteria alongside new knowledge on PNS obtained from published and unpublished data generated by the different laboratories involved in the project. RESULTS: The panel proposed to substitute "classical syndromes" with the term "high-risk phenotypes" for cancer and introduce the concept of "intermediate-risk phenotypes." The term "onconeural antibody" was replaced by "high risk" (>70% associated with cancer) and "intermediate risk" (30%-70% associated with cancer) antibodies. The panel classified 3 levels of evidence for PNS: definite, probable, and possible. Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up. With the exception of opsoclonus-myoclonus, the diagnosis of definite PNS requires the presence of high- or intermediate-risk antibodies. Specific recommendations for similar syndromes triggered by immune checkpoint inhibitors are also provided. CONCLUSIONS: The proposed criteria and recommendations should be used to enhance the clinical care of patients with PNS and to encourage standardization of research initiatives addressing PNS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/nxi.0000000000001014

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 759

Metadata

Authors
Graus, F., Vogrig, A., Muñiz-Castrillo, S., Antoine, J.-C. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., McKeon, A., Prüss, H., Psimaras, D., Thomas, L., Titulaer, M. J., Vedeler, C. A., Verschuuren, J. J., Dalmau, J., & Honnorat, J.
Venue
Neurology Neuroimmunology & Neuroinflammation
Published
2021-07
Volume
8
Issue
4
ISSN
2332-7812 (ISSN-L)
OpenAlex
W3163926470
Cited by
759
References
50
FWCI
46.98
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. https://app.cochat.ai/papers/10.1212/nxi.0000000000001014
The paper
Graus, F., Vogrig, A., Muñiz-Castrillo, S., Antoine, J.-C. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., McKeon, A., Prüss, H., Psimaras, D., Thomas, L., Titulaer, M. J., Vedeler, C. A., Verschuuren, J. J., Dalmau, J., & Honnorat, J. (2021). Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000001014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.